Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s187615
Abstract: Purpose Pancreatic cancer is characterized by a hypoxic microenvironment and resistance to most currently available treatment modalities. Prolyl hydroxylase domain 3 (PHD3) is a rate-limiting enzyme that regulates the degradation of hypoxia-inducible factors (HIFs) and… read more here.
Keywords: radiotherapy efficacy; hypoxia; pancreatic cancer; efficacy pancreatic ... See more keywords